This supports the hypothesis that a higher tumor mutational burden (TMB) presented by EGFR-TKI acquired resistance results in an increase of immunogenic neo-antigens, in turn affects the TCR clonality of CD39 + CD8 + T cells in MPE. This evidence concerns the gene ENTPD1 and neoplasm.